Lipoprotein(a) as a Higher Residual Risk for Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus than without

References

• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–2381. doi:10.1093/eurheartj/ehw106
   PubMed Web of Science ®Google Scholar
• Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164(13):1422–1426. doi:10.1001/archinte.164.13.1422
   PubMedGoogle Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–2581. doi:10.1001/jama.287.19.2570
   PubMed Web of Science ®Google Scholar
• Cai X, Zhang Y, Li M, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. doi:10.1136/bmj.m2297
   PubMed Web of Science ®Google Scholar
• Cai X, Liu X, Sun L, et al. Prediabetes and the risk of heart failure: a meta-analysis. Diabetes Obes Metab. 2021;23(8):1746–1753. doi:10.1111/dom.14388
   PubMed Web of Science ®Google Scholar
• Ma T, Huang X, Zheng H, et al. SFRP2 improves mitochondrial dynamics and mitochondrial biogenesis, oxidative stress, and apoptosis in diabetic cardiomyopathy. Oxid Med Cell Longev. 2021;2021:9265016. doi:10.1155/2021/9265016
   PubMed Web of Science ®Google Scholar
• Wu J, Zheng H, Liu X, et al. Prognostic value of secreted frizzled-related protein 5 in heart failure patients with and without type 2 diabetes mellitus. Circ Heart Fail. 2020;13(9):e007054. doi:10.1161/CIRCHEARTFAILURE.120.007054
   PubMed Web of Science ®Google Scholar
• Mai L, Wen W, Qiu M, et al. Association between prediabetes and adverse outcomes in heart failure. Diabetes Obes Metab. 2021;23(11):2476–2483. doi:10.1111/dom.14490
   PubMed Web of Science ®Google Scholar
• Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496–1504. doi:10.2337/diacare.27.6.1496
   PubMed Web of Science ®Google Scholar
• Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25(9):771–782. doi:10.5551/jat.RV17023
   PubMed Web of Science ®Google Scholar
• Thambiah SC, Lai LC. Diabetic dyslipidaemia. Pract Lab Med. 2021;26:e00248. doi:10.1016/j.plabm.2021.e00248
   PubMedGoogle Scholar
• Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003;46(6):733–749. doi:10.1007/s00125-003-1111-y
   PubMed Web of Science ®Google Scholar
• Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711. doi:10.1016/j.jacc.2016.11.042
   PubMed Web of Science ®Google Scholar
• Mehta A, Virani SS, Ayers CR, et al. Lipoprotein(a) and family history predict cardiovascular disease risk. J Am Coll Cardiol. 2020;76(7):781–793. doi:10.1016/j.jacc.2020.06.040
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–2853. doi:10.1093/eurheartj/ehq386
   PubMed Web of Science ®Google Scholar
• Jang AY, Han SH, Sohn IS, Oh PC, Koh KK. Lipoprotein(a) and cardiovascular diseases- revisited. Circ J. 2020;84(6):867–874. doi:10.1253/circj.CJ-20-0051
   PubMed Web of Science ®Google Scholar
• Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein(a): an update on a marker of residual risk and associated clinical manifestations. Am J Cardiol. 2020;126:94–102. doi:10.1016/j.amjcard.2020.03.043
   PubMed Web of Science ®Google Scholar
• Hu X, Yang X, Li X, Luo D, Zhou Y, Dong H. Lipoprotein(a) as a residual risk factor for atherosclerotic renal artery stenosis in hypertensive patients: a hospital-based cross-sectional study. Lipids Health Dis. 2020;19(1):173. doi:10.1186/s12944-020-01272-0
   PubMed Web of Science ®Google Scholar
• Kelly E, Hemphill L. Lipoprotein(a): a lipoprotein whose time has come. Curr Treat Options Cardiovasc Med. 2017;19(7):48. doi:10.1007/s11936-017-0549-z
   PubMedGoogle Scholar
• Ye Z, Haycock PC, Gurdasani D, et al. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes. 2014;63(1):332–342. doi:10.2337/db13-1144
   PubMed Web of Science ®Google Scholar
• Paige E, Masconi KL, Tsimikas S, et al. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16(1):38. doi:10.1186/s12933-017-0520-z
   PubMedGoogle Scholar
• Gudbjartsson DF, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74(24):2982–2994. doi:10.1016/j.jacc.2019.10.019
   PubMed Web of Science ®Google Scholar
• Habib SS, Aslam M. Lipids and lipoprotein(a) concentrations in Pakistani patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2004;6(5):338–343. doi:10.1111/j.1462-8902.2004.00352.x
   PubMed Web of Science ®Google Scholar
• Zhang HW, Zhao X, Guo YL, et al. Elevated lipoprotein(a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2018;28(10):980–986. doi:10.1016/j.numecd.2018.05.010
   PubMed Web of Science ®Google Scholar
• Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017;38(32):2490–2498. doi:10.1093/eurheartj/ehx166
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi:10.1093/eurheartj/ehy339
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S17–S38. doi:10.2337/dc22-S002
   PubMedGoogle Scholar
• Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 appropriate use criteria for coronary revascularization in patients with acute coronary syndromes: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons. J Nucl Cardiol. 2017;24(2):439–463. doi:10.1007/s12350-017-0780-8
   PubMedGoogle Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16(2):434–444. doi:10.2337/diacare.16.2.434
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jin JL, Cao YX, et al. Lipoprotein(a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study. Cardiovasc Diabetol. 2020;19(1):111. doi:10.1186/s12933-020-01083-8
   PubMed Web of Science ®Google Scholar
• Jin JL, Cao YX, Zhang HW, et al. Lipoprotein(a) and cardiovascular outcomes in patients with coronary artery disease and prediabetes or diabetes. Diabetes Care. 2019;42(7):1312–1318. doi:10.2337/dc19-0274
   PubMed Web of Science ®Google Scholar
• Sawabe M, Tanaka N, Nakahara K, et al. High lipoprotein(a) level promotes both coronary atherosclerosis and myocardial infarction: a path analysis using a large number of autopsy cases. Heart. 2009;95(24):1997–2002. doi:10.1136/hrt.2008.160879
   PubMed Web of Science ®Google Scholar
• Peela JR, Latiwesh OB, Elshaari F, et al. Investigating the atherogenic risk of lipoprotein(a) in type 2 diabetic patients. Cureus. 2018;10(7):e3030. doi:10.7759/cureus.3030
   PubMed Web of Science ®Google Scholar
• Lan NSR, Chan DC, Pang J, et al. Lipoprotein(a) in patients with type 2 diabetes and premature coronary artery disease in the coronary care unit. Heart Lung Circ. 2021;30(5):734–740. doi:10.1016/j.hlc.2020.09.932
   PubMed Web of Science ®Google Scholar
• Fu Q, Hu L, Xu Y, Yi Y, Jiang L. High lipoprotein(a) concentrations are associated with lower type 2 diabetes risk in the Chinese Han population: a large retrospective cohort study. Lipids Health Dis. 2021;20(1):76. doi:10.1186/s12944-021-01504-x
   PubMed Web of Science ®Google Scholar
• Rainwater DL, Haffner SM. Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arterioscler Thromb Vasc Biol. 1998;18(8):1335–1341. doi:10.1161/01.ATV.18.8.1335
   PubMed Web of Science ®Google Scholar
• Neele T2DM, de Wit EC, Princen HM. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes. Diabetologia. 1999;42(1):41–44. doi:10.1007/s001250051110
   PubMed Web of Science ®Google Scholar
• Wang C, Niu DM, Hu J, et al. Elevated serum β2-glycoprotein-I-lipoprotein(a) complexes levels are associated with the presence and complications in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2013;100(2):250–256. doi:10.1016/j.diabres.2013.03.002
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2013;1(3):220–227. doi:10.1016/S2213-8587(13)70064-0
   PubMed Web of Science ®Google Scholar
• Markus MRP, Ittermann T, Schipf S, et al. Association of sex-specific differences in lipoprotein(a) concentrations with cardiovascular mortality in individuals with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1):168. doi:10.1186/s12933-021-01363-x
   PubMed Web of Science ®Google Scholar
• Bennion LJ, Drobny E, Knowler WC, et al. Sex differences in the size of bile acid pools. Metabolism. 1978;27(8):961–969. doi:10.1016/0026-0495(78)90140-3
   PubMed Web of Science ®Google Scholar
• Pirillo A, Catapano AL. Statins increase Lp(a) plasma level: is this clinically relevant? Eur Heart J. 2020;41(24):2285–2287. doi:10.1093/eurheartj/ehz505
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Chen S, Luan H, He J, et al. Serum concentrations of small dense low-density lipoprotein cholesterol and lipoprotein(a) are related to coronary arteriostenosis in Takayasu arteritis. J Clin Lab Anal. 2021;35(12):e23966. doi:10.1002/jcla.23966
   PubMed Web of Science ®Google Scholar
• Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the Jupiter trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation. 2014;129(6):635–642. doi:10.1161/CIRCULATIONAHA.113.004406
   PubMed Web of Science ®Google Scholar